Tamid Bio, Inc., a subsidiary of Fortress Biotech, is a New York-based company dedicated to developing adeno-associated virus (AAV) gene therapies for orphan diseases with unmet medical needs. Partnering with the University of North Carolina at Chapel Hill (UNC-Chapel Hill) and the UNC Gene Therapy Center, Tamid is focused on the development of Tamid-001, an AAV gene therapy targeting the ocular manifestations of Mucopolysaccharidosis type I (MPS I), a rare and debilitating disorder caused by the accumulation of glycosaminoglycans (GAGs) in multiple organs.
In addition to Tamid-001, Tamid has also in-licensed two earlier-stage assets from UNC-Chapel Hill, which aim to address dysferlinopathies and corneal transplant rejection. Preclinical and early clinical research programs for these assets will be conducted at the UNC Gene Therapy Center, furthering Tamid's commitment to developing innovative gene therapies for orphan diseases.
Generated from the website